Conivaptan: promise of treatment in heart failure.
Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients. The renin-angiotensin-aldosterone system is activated in heart failure (HF) causing clinical worsening. Arginine vasopressin levels are also elevated in HF. Conivaptan is an effective and FDA approved for the treatment of euvolemic and hypervolemic hyponatremia and may offer an extra treatment option in HF by targeting V(1a) and V(2) receptors. In this article we review the physiology, preclinical studies as well as the human clinical studies on the use of conivaptan and its potential and promise in the treatment of HF.
Hoque
Mohammad Z
MZ
Albert Einstein Medical Center, Cardiology, 5501 Old York Road, Philadelphia, PA 19141, USA.
Arumugham
Pradeep
P
Huda
Nazmul
N
Verma
Nitin
N
Afiniwala
Mitul
M
Karia
Darshak H
DH
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000503:physiopathology; D017483:Receptors, Vasopressin / Q000145:classification / Q000502:physiology
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D017483:Receptors, Vasopressin; C106389:conivaptan